On May 17, Ali Health officially released the 2017 annual performance report. Compared with previous years, this year's report is a lot brighter. For the year ended March 31, 2017, Ali Health recorded revenue of 475.1 million yuan (RMB, the same below), gross profit of 187.2 million yuan, gross margin of 39.1%, a year-on-year increase of 739.4% and 392.8%, and the company's adjusted net loss fell sharply by 39.1% year-on-year to 98.33 million yuan.
In the income, it is mainly composed of two businesses, one is the pharmaceutical e-commerce business, and the other is the product tracking system “code-safe†business.
In the pharmaceutical e-commerce business, the company earned 378 million yuan in the current fiscal year, mainly including pharmaceutical B2C business, Tmall medical clinic medical related category outsourcing and value-added services, collection and distribution business and others. Among them, pharmaceutical B2C business income was 291 million, accounting for 61.2% of total revenue, and the gross profit margin of this business was 26.7%.
In August 2016, Ali Health completed the acquisition of the B2C pharmacy business by Guangzhou Wujiu Pharmaceutical Chain Co., Ltd. (later renamed Ali Health Pharmacy), which has a C-type Internet drug trading service qualification certificate. This means that for half a year, Ali Health Pharmaceutical B2C business realized a revenue of 291 million yuan, which is estimated to be about 600 million yuan. According to Medical Valley, Ali Health relies on Tmall's natural advantages over other companies' pharmaceutical B2C platforms, which is far lower than other medical e-commerce companies in terms of flow cost acquisition.
In September 2016, the Ali Health Shareholders' General Meeting voted through Ali Health to provide a full range of outsourcing and value-added services for the TCM Medical Category related categories, assisting Tmall to develop its medical e-commerce business and charge fees. The specific cost ratio is 21.5% of the expenses paid by the merchant to the Tmall entity based on the sales of the products or services through which the Tmall sales related products are sold. According to the financial report, for the year ended March 31, 2017, Ali Health The service fee from Tmall is 40.34 million yuan, and it is expected to reach 80 million in the whole year.
Ali's other business income source mainly comes from the product traceability platform “code assured†business. According to the financial report, the income of this year was 96.3 million yuan, and the income of the previous year was 56.59 million yuan, which was 170% growth. The platform's customers have expanded from the pharmaceutical industry to non-pharmaceutical industries such as food, agricultural products and tonics. As of the end of the year, more than 5,000 companies including pharmaceuticals, food, and tonics have signed up with Ali Health to settle on the code. It is worth noting that the financial report indicates that the number of pharmaceutical manufacturers that have settled in the “code is assured†has exceeded half of the total number of pharmaceutical manufacturers in China. Therefore, compared with the original electronic code of drug control, Ali Health has gained a broader space for development on the basis of the original code.
ZHEJIANG SHENDASIAO MEDICAL INSTRUMENT CO.,LTD. , https://www.shendasiaomed.com